Skip to search formSkip to main contentSkip to account menu

AG 1343

Known as: AG-1343, AG1343 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
  • 2005
  • Corpus ID: 34900645
1995
1995
: Early study results show that the protease inhibitor AG1343, being developed by Agouron Pharmaceuticals of La Jolla, California… 
1995
1995
Based on favorable results from a phase I study of AG1343 using oral doses of 800 mg and 400 mg, a new study assessed a 300 mg… 
1995
1995
Hoffmann-La Roche and Agouron Pharmaceuticals are establishing large clinical studies in the United States of their protease… 
1995
1995
Three new protease inhibitors stand out in light of cross-resistance, either because they achieve levels in the blood that may… 
1995
1995
Presentation highlights are provided from the Nineteenth International Congress on Chemotherapy in Montreal. Some of the new… 
1995
1995
There are several ongoing protease inhibitor trials for individuals with HIV. Hoffmann-LaRoche's trial of saquinavir is a phase… 
1995
1995
1995
Early study results show that the protease inhibitor AG1343, being developed by Agouron Pharmaceuticals of La Jolla, California… 
1995
1995
Protease inhibitors (PRIs) are a diverse group of drugs which block an HIV-1 enzyme needed for the production of new viruses…